Skip to main content

Table 3 Postoperative course and complications (N = 70)a

From: The Carpentier-Edwards Perimount Magna mitral valve bioprosthesis: intermediate-term efficacy and durability

Hospital LOS,b days

11.6 ± 0.8

Cardiogenic shockc

6 (8.6 %)

IABP use

2 (2.9 %)

Tracheostomy

4 (5.7 %)

Any renal failure

17 (24 %)

Renal failure requiring dialysis

6 (8.6 %)

Reoperation for bleed

4 (5.7 %)

AF

50 (71 %)

Heart block

19 (27 %)

 Transient

16 (23 %)

 Permanent pacer

3 (4.2 %)

Wound infection

1 (1.4 %)

Cardiac arrest

3 (4.3 %)

In-hospital death

5 (7.1 %)

Stroke

2 (2.9 %)

Valve-related complications

 

 Thrombosis

0 (0 %)

 Dehiscence

0 (0 %)

 LVOTOd

1 (1.4 %)

 Vegetations

0 (0 %)

 AV groove disruption

1 (1.4 %)

  1. AF atrial fibrillation, AV atrioventricular, IABP intraaortic balloon pump, LOS length of stay, LVOTO left ventricular outflow tract obstruction
  2. aContinuous variables expressed as mean ± standard error of the mean (SE); categorical variables, as n (percentage)1
  3. bData available for only 65 patients
  4. cData available for only 69 patients
  5. dRequired reoperation at 2 years